COMPANY

ViTToria Biotherapeutics

HQ: Philadelphia, PA source · vittoriabio.com ↗ · Mid-Atlantic

Keywords: oncology immunology T Cell Non-Hodgkin Lymphoma Senza5 CART5

Location: Philadelphia, PA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Undisclosed round · $25M · announced Nov 22, 2024 Company release ↗
Source quote
- Nov 22, 2024 · Company release ↗
  “Vittoria Biotherapeutics Completes $25 Million in Private Financing to Propel Groundbreaking Cell Therapy Candidates Funding to support clinical proof-of-concept for the lead program”
Raise Undisclosed round · more than $15M · announced Oct 12, 2024 Company release ↗
Source quote
- Oct 12, 2024 · Company release ↗
  “Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies Funds to support advancement of lead candidate”

Raises announced in these releases: $40M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Nov 22, 2024 Raise Private equity round: $25M (total, as published), announced Nov 22, 2024. Source: company's own press page. source ↗
Nov 22, 2024 Raise Undisclosed round · $25M source ↗
Oct 12, 2024 Raise Private equity round: $15M (total, as published), announced Oct 12, 2024. Source: company's own press page. source ↗
Oct 12, 2024 Raise Undisclosed round · more than $15M source ↗
Oct 4, 2024 Trial start Phase 1: CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) source ↗
2026-07 Trial start —: A Long-Term Follow-Up Trial for Participants Enrolled in CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) Trials source ↗

Aug 30, 2028 (ESTIMATED) · Phase 1 · CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) · NCT06420089
2041-07 (ESTIMATED) · · A Long-Term Follow-Up Trial for Participants Enrolled in CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) Trials · NCT07683897

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $40.0M. Last 2 years.

Nov 22, 2024 Private equity round: $25M (total, as published), announced Nov 22, 2024. Source: company's own press page. source ↗
Oct 12, 2024 Private equity round: $15M (total, as published), announced Oct 12, 2024. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07683897	A Long-Term Follow-Up Trial for Participants Enrolled in CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) Trials	Not listed	Not yet recruiting	2026-07	2041-07 (estimated)
NCT06420089	CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)	Phase 1	Recruiting	Oct 4, 2024	Aug 30, 2028 (estimated)